124685-36-5

Upstream product

• 1892-29-1 bis(2-hydroxyethyl) disulfide 
• 40615-36-9 4,4'-dimethoxytrityl chloride 

Downstream Products

• 124685-37-6 Succinic acid 2-{2-[bis-(4-methoxy-phenyl)-phenyl-methoxy]-ethyldisulfanyl}-ethyl ester 4-nitro-phenyl ester 
• 124685-38-7 13-bis(4-methoxyphenyl)-13-phenyl-4-oxo-8,9-dithia-5,12-dioxatridecanoic acid 
• 1426657-85-3 C₃₅H₃₁N₃O₈S₂ 
• 1611489-98-5 C₆₀H₆₀N₄O₁₁S₃ 
• 1611489-99-6 C₅₈H₆₀N₂O₁₀S₂ 

Relevant academic research and scientific papers

A useful disulfide linker for single-bead analysis of peptide libraries

A disulfide-linker for conventional peptide synthesis, attached to a PEGA-resin, has been developed. Reductive hydrolysis cleaves the linker within minutes, liberating the synthesized peptide for rapid sequencing by tandem mass spectrometry. The method has been tested for ten peptides in a single-bead fashion.

GSH Induced Controlled Release of Levofloxacin from a Purpose-Built Prodrug: Luminescence Response for Probing the Drug Release in Escherichia coli and Staphylococcus aureus

Fluoroquinolones are third-generation broad spectrum bactericidal antibiotics and work against both Gram-positive and Gram-negative bacteria. Levofloxacin (L), a fluoroquinolone, is widely used in anti-infective chemotherapy and treatment of urinary tract infection and pneumonia. The main pathogen for urinary tract infections is Escherichia coli, and Streptococcus pneumoniae is responsible for pneumonia, predominantly a lower respiratory tract infection. Poor permeability of L leads to the use of higher dose of this drug and excess drug in the outer cellular fluid leads to central nervous system (CNS) abnormality. One way to counter this is to improve the lipophilicity of the drug molecule, and accordingly, we have synthesized two new Levofloxacin derivatives, which participated in the spatiotemporal release of drug via disulfide bond cleavage induced by glutathione (GSH). Recent studies with Streptococcus mutants suggest that it is localized in epithelial lining fluid (ELF) of the normal lower respiratory tract and the effective [GSH] in ELF is ～430 μM. E. coli typically cause urinary tract infections and the concentration of GSH in porcine bladder epithelium is reported as 0.6 mM for a healthy human. Thus, for the present study we have chosen two important bacteria (Gram + ve and Gram - ve), which are operational in regions having high extracellular GSH concentration. Interestingly, this supports our design of new lipophilic Levofloxacin based prodrugs, which released effective drug on reaction with GSH. Higher lipophilicity favored improved uptake of the prodrugs. Site specific release of the drug (L) could be achieved following a glutathione mediated biochemical transformation process through cleavage of a disulfide bond of these purpose-built prodrugs. Further, appropriate design helped us to demonstrate that it is possible also to control the kinetics of the drug release from respective prodrugs. Associated luminescence enhancement helps in probing the release of the drug from the prodrug in bacteria and helps in elucidating the mechanistic pathway of the transformation. Such an example is scarce in the contemporary literature.

Solid-phase preparation of 5',3'-heterobifunctional oligodeoxyribonucleotides using modified solid supports

The solid-phase preparation of oligodeoxyribonucleotides attached to intercalator or reactive groups through their 5'- and (or) 3'-ends is reported. These syntheses implicate the introduction of suitable masked functional groups at the 5'-end of the oligo